These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2261347)

  • 41. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
    Belch A; Shelley W; Bergsagel D; Wilson K; Klimo P; White D; Willan A
    Br J Cancer; 1988 Jan; 57(1):94-9. PubMed ID: 3279997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
    Gola A; Usnarska-Zubkiewicz L; Wołowiec D; Urbaniak-Kujda D; Kotlarek-Haus S
    Pol Arch Med Wewn; 1993 Aug; 90(2):134-41. PubMed ID: 8247946
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
    Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M;
    Lancet; 2006 Mar; 367(9513):825-31. PubMed ID: 16530576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
    Ahre A; Björkholm M; Mellstedt H; Holm G; Brenning G; Engstedt L; Gahrton G; Hällen J; Johansson B; Johansson SG; Karnström L; Killander A; Lerner R; Lockner D; Lönnqvist B; Simonsson B; Stalfelt AM; Ternstedt B; Wadman B
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):499-506. PubMed ID: 6345174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination therapy of M2-protocol and interferon-alpha as remission induction in refractory multiple myeloma.
    Shimamoto Y; Matsuzaki M; Ono K; Sano M; Yamaguchi M
    Haematologia (Budap); 1991; 24(1):9-11. PubMed ID: 1813363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Study on the therapy of multiple myelomas--initial induction therapy (MP, IFN alpha, steroid pulse) and maintenance therapy (VMP, MP continuous, VEP, MCNU)].
    Tanaka H; Kawano M; Iwato K; Asaoku H; Tanabe O; Ishikawa H; Nobuyoshi M; Sakai A; Kuramoto A
    Rinsho Ketsueki; 1992 May; 33(5):655-61. PubMed ID: 1630017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of interferon in the treatment of multiple myeloma.
    Costanzi JJ; Pollard RB
    Semin Oncol; 1987 Jun; 14(2 Suppl 2):24-8. PubMed ID: 3296211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
    Wijermans P; Schaafsma M; Termorshuizen F; Ammerlaan R; Wittebol S; Sinnige H; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst H; Sonneveld P;
    J Clin Oncol; 2010 Jul; 28(19):3160-6. PubMed ID: 20516439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
    Dimopoulos MA; Weber D; Delasalle KB; Alexanian R
    Cancer; 1993 Nov; 72(9):2589-92. PubMed ID: 8402480
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A case of multiple myeloma with nuclear hypersegmentation after MP/VAD/VCAP-IFN therapies with a good prognosis.
    Nara M; Suzuki K; Inoue Y; Enomoto H; Saito T; Fujioka S
    Acta Haematol; 1993; 90(2):102-3. PubMed ID: 8285014
    [No Abstract]   [Full Text] [Related]  

  • 53. A review of the clinical studies of alpha-interferon in the management of multiple myeloma.
    Cooper MR
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):18-29. PubMed ID: 1948125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.
    Hernández JM; García-Sanz R; Golvano E; Bladé J; Fernandez-Calvo J; Trujillo J; Soler JA; Gardella S; Carbonell F; Mateo G; San Miguel JF
    Br J Haematol; 2004 Oct; 127(2):159-64. PubMed ID: 15461621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan.
    Wada M; Mizoguchi H; Kuriya SI; Taguchi H; Kawamura T; Maekawa I; Shimazaki C; Sato Y; Niho Y; Miyazaki T; Shibata A; Kitani T; Hamajima N; Ohno R
    Br J Haematol; 2000 Jun; 109(4):805-14. PubMed ID: 10929034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Dimopoulos MA; Richardson PG; Schlag R; Khuageva NK; Shpilberg O; Kastritis E; Kropff M; Petrucci MT; Delforge M; Alexeeva J; Schots R; Masszi T; Mateos MV; Deraedt W; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2009 Dec; 27(36):6086-93. PubMed ID: 19858394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.
    Kapoor P; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Mikhael JR; Roy V; Kyle RA; Greipp PR; Kumar S; Mandrekar SJ
    Leukemia; 2011 Apr; 25(4):689-96. PubMed ID: 21233832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
    J Clin Oncol; 1998 Dec; 16(12):3832-42. PubMed ID: 9850028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
    Ludwig H; Spicka I; Klener P; Greil R; Adam Z; Gisslinger H; Tarkovács G; Linkesch W; Maniatis A; Morant R; Drach J; Kuhn I; Schuster J; Hinke A
    Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
    Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.